* Alto Neuroscience press release [https://seekingalpha.com/pr/20200203-alto-neuroscience-reports-second-quarter-2025-financial-results-and-recent-business] (NYSE:ANRO [https://seekingalpha.com/symbol/ANRO]): Q2 GAAP EPS of -$0.65.
*
As of June 30, 2025 the Company had cash, cash equivalents, and restricted cash of approximately $148.1 million, compared to approximately $168.7 million in cash, cash equivalents, and restricted cash as of December 31, 2024.
The Company expects its cash balance to support planned operations into 2028.
R&D Expenses: Research and development expenses for the quarter ended June 30, 2025 were $13.1 million, as compared to $13.2 million for the same period in 2024.
G&A Expenses: General and administrative expenses for the quarter ended June 30, 2025 were $5.6 million, as compared to $5.2 million for the same period in 2024.
*
MORE ON ALTO NEUROSCIENCE
* Seeking Alpha’s Quant Rating on Alto Neuroscience [https://seekingalpha.com/symbol/ANRO/ratings/quant-ratings]
* Historical earnings data for Alto Neuroscience [https://seekingalpha.com/symbol/ANRO/earnings]
* Financial information for Alto Neuroscience [https://seekingalpha.com/symbol/ANRO/income-statement]
Alto Neuroscience GAAP EPS of -$0.65
Published 2 months ago
Aug 13, 2025 at 8:46 PM
Positive
Auto